Synbio Tech Inc.
Synbio Tech Inc. manufactures and sells human healthcare products and probiotics for animals. It offers lactobacillus plantarum powder and derivatives of fermented lactic acid bacteria, as well as probiotics for dietary supplements, pets, economic animals, and plant preservation. The company also provides single probiotic strain and multi strain probiotics, and functional strain. Its functional s… Read more
Synbio Tech Inc. (1295) - Net Assets
Latest net assets as of September 2025: NT$1.27 Billion TWD
Based on the latest financial reports, Synbio Tech Inc. (1295) has net assets worth NT$1.27 Billion TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$2.85 Billion) and total liabilities (NT$1.58 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.27 Billion |
| % of Total Assets | 44.53% |
| Annual Growth Rate | 9.22% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 4.83 |
Synbio Tech Inc. - Net Assets Trend (2020–2024)
This chart illustrates how Synbio Tech Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Synbio Tech Inc. (2020–2024)
The table below shows the annual net assets of Synbio Tech Inc. from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.08 Billion | +14.47% |
| 2023-12-31 | NT$942.97 Million | +5.04% |
| 2022-12-31 | NT$897.68 Million | +4.00% |
| 2021-12-31 | NT$863.17 Million | +13.81% |
| 2020-12-31 | NT$758.45 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Synbio Tech Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 126.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$425.06 Million | 39.38% |
| Common Stock | NT$313.55 Million | 29.05% |
| Other Components | NT$340.81 Million | 31.57% |
| Total Equity | NT$1.08 Billion | 100.00% |
Synbio Tech Inc. Competitors by Market Cap
The table below lists competitors of Synbio Tech Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
YAHOO JAPAN
BE:YOJ
|
$21.16K |
|
Human Xtensions Ltd
TA:HUMX
|
$21.16K |
|
Baron Capital
PINK:BCAP
|
$21.16K |
|
MILS3F
SA:MILS3F
|
$21.17K |
|
KEY TRONIC
BE:KT1
|
$21.12K |
|
ARYZTA N
MU:YZA
|
$21.08K |
|
Crystalvue Medical Corporation
TWO:6527
|
$21.08K |
|
TAURON
MU:1T5
|
$21.07K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Synbio Tech Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 942,969,000 to 1,079,425,000, a change of 136,456,000 (14.5%).
- Net income of 170,125,000 contributed positively to equity growth.
- Dividend payments of 46,110,000 reduced retained earnings.
- Other factors increased equity by 12,441,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$170.12 Million | +15.76% |
| Dividends Paid | NT$46.11 Million | -4.27% |
| Other Changes | NT$12.44 Million | +1.15% |
| Total Change | NT$- | 14.47% |
Book Value vs Market Value Analysis
This analysis compares Synbio Tech Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.09x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.96x to 2.09x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | NT$24.19 | NT$71.50 | x |
| 2021-12-31 | NT$27.68 | NT$71.50 | x |
| 2022-12-31 | NT$28.50 | NT$71.50 | x |
| 2023-12-31 | NT$29.97 | NT$71.50 | x |
| 2024-12-31 | NT$34.27 | NT$71.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Synbio Tech Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.76%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 17.19%
- • Asset Turnover: 0.42x
- • Equity Multiplier: 2.17x
- Recent ROE (15.76%) is above the historical average (14.80%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 17.38% | 17.87% | 0.53x | 1.83x | NT$55.96 Million |
| 2021 | 18.53% | 18.69% | 0.56x | 1.78x | NT$73.65 Million |
| 2022 | 10.31% | 12.51% | 0.44x | 1.87x | NT$2.75 Million |
| 2023 | 12.01% | 13.76% | 0.44x | 2.00x | NT$18.97 Million |
| 2024 | 15.76% | 17.19% | 0.42x | 2.17x | NT$62.18 Million |
Industry Comparison
This section compares Synbio Tech Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,078,632,556
- Average return on equity (ROE) among peers: 6.91%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Synbio Tech Inc. (1295) | NT$1.27 Billion | 17.38% | 1.25x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |